BRPI0820406A2 - Methods to identify increased nmda receptor antagonists - Google Patents
Methods to identify increased nmda receptor antagonistsInfo
- Publication number
- BRPI0820406A2 BRPI0820406A2 BRPI0820406-3A BRPI0820406A BRPI0820406A2 BR PI0820406 A2 BRPI0820406 A2 BR PI0820406A2 BR PI0820406 A BRPI0820406 A BR PI0820406A BR PI0820406 A2 BRPI0820406 A2 BR PI0820406A2
- Authority
- BR
- Brazil
- Prior art keywords
- methods
- receptor antagonists
- nmda receptor
- identify increased
- increased nmda
- Prior art date
Links
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 title 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/84—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving inorganic compounds or pH
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70571—Assays involving receptors, cell surface antigens or cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2857—Seizure disorders; Epilepsy
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2871—Cerebrovascular disorders, e.g. stroke, cerebral infarct, cerebral haemorrhage, transient ischemic event
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Analytical Chemistry (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Pain & Pain Management (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US98592407P | 2007-11-06 | 2007-11-06 | |
| US98592207P | 2007-11-06 | 2007-11-06 | |
| PCT/US2008/082660 WO2009061935A2 (en) | 2007-11-06 | 2008-11-06 | Methods of identifying safe nmda receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0820406A2 true BRPI0820406A2 (en) | 2015-05-19 |
Family
ID=40626437
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0820406-3A BRPI0820406A2 (en) | 2007-11-06 | 2008-11-06 | Methods to identify increased nmda receptor antagonists |
Country Status (12)
| Country | Link |
|---|---|
| EP (1) | EP2212694A4 (en) |
| JP (1) | JP2011503013A (en) |
| KR (1) | KR20100100858A (en) |
| CN (1) | CN101918832A (en) |
| AU (1) | AU2008323877A1 (en) |
| BR (1) | BRPI0820406A2 (en) |
| CA (1) | CA2704475A1 (en) |
| EA (1) | EA201070571A1 (en) |
| IL (1) | IL205432A0 (en) |
| MX (1) | MX2010004971A (en) |
| WO (1) | WO2009061935A2 (en) |
| ZA (1) | ZA201003724B (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014159960A (en) * | 2011-06-08 | 2014-09-04 | Astellas Pharma Inc | Automatic measurement method for spontaneous pain action of chronic pain model animal |
| SG10202007661XA (en) * | 2015-05-22 | 2020-09-29 | Vistagen Therapeutics Inc | Therapeutic uses of l-4-chlorokynurenine |
| US10583171B2 (en) | 2015-11-30 | 2020-03-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | NMDAR antagonists for the treatment of diseases associated with angiogenesis |
| CN111960514A (en) * | 2020-08-28 | 2020-11-20 | 浙江浙能技术研究院有限公司 | A kind of electrodialysis intelligent control system and method for desulfurization wastewater concentration |
| EP4395783A4 (en) | 2021-09-02 | 2025-11-26 | Univ Emory | Selective antagonists of the N-methyl-D-aspartate receptors of the GLUN2B subunit with increased potency at acidic pH |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002072542A2 (en) * | 2001-03-08 | 2002-09-19 | Emory University | Ph-dependent nmda receptor antagonists |
| KR20030063765A (en) * | 2002-01-24 | 2003-07-31 | 엘지전자 주식회사 | Objective Lens for Pick Up System |
| UY27939A1 (en) * | 2002-08-21 | 2004-03-31 | Glaxo Group Ltd | COMPOUNDS |
| CN1894279A (en) * | 2003-12-16 | 2007-01-10 | 安万特药物公司 | secreted inhibitor of neuroapoptosis protein |
| WO2006023957A1 (en) * | 2004-08-23 | 2006-03-02 | Emory University | Improved selection of-ph dependent compounds for in vivo therapy |
-
2008
- 2008-11-06 MX MX2010004971A patent/MX2010004971A/en active IP Right Grant
- 2008-11-06 BR BRPI0820406-3A patent/BRPI0820406A2/en not_active IP Right Cessation
- 2008-11-06 EA EA201070571A patent/EA201070571A1/en unknown
- 2008-11-06 CA CA2704475A patent/CA2704475A1/en not_active Abandoned
- 2008-11-06 EP EP08847388A patent/EP2212694A4/en not_active Withdrawn
- 2008-11-06 AU AU2008323877A patent/AU2008323877A1/en not_active Abandoned
- 2008-11-06 KR KR1020107012419A patent/KR20100100858A/en not_active Withdrawn
- 2008-11-06 WO PCT/US2008/082660 patent/WO2009061935A2/en not_active Ceased
- 2008-11-06 CN CN2008801240927A patent/CN101918832A/en active Pending
- 2008-11-06 JP JP2010532343A patent/JP2011503013A/en active Pending
-
2010
- 2010-04-29 IL IL205432A patent/IL205432A0/en unknown
- 2010-05-25 ZA ZA2010/03724A patent/ZA201003724B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2704475A1 (en) | 2009-05-14 |
| EA201070571A1 (en) | 2010-12-30 |
| JP2011503013A (en) | 2011-01-27 |
| MX2010004971A (en) | 2010-07-28 |
| KR20100100858A (en) | 2010-09-15 |
| EP2212694A4 (en) | 2011-10-12 |
| EP2212694A2 (en) | 2010-08-04 |
| WO2009061935A3 (en) | 2009-08-20 |
| CN101918832A (en) | 2010-12-15 |
| AU2008323877A1 (en) | 2009-05-14 |
| WO2009061935A2 (en) | 2009-05-14 |
| IL205432A0 (en) | 2010-12-30 |
| ZA201003724B (en) | 2013-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LTPA2020513I1 (en) | S1P receptor agonist dosing | |
| BRPI0913930A2 (en) | prostaglandin d2 receptor antagonists | |
| BRPI0910118A2 (en) | glucagon receptor antagonists | |
| EP2150115A4 (en) | RECEPTOR ANTAGONISTS OF CYCLOPROPYLPYRROLIDINE OREXINE | |
| DK2821407T3 (en) | PIPERIDINONCARBOXAMIDAZAINDAN-CGRP RECEPTOR ANTAGONISTS | |
| ATE524460T1 (en) | PYRIDONE-GPR119-G PROTEIN-COUPLED RECEPTOR AGONISTS | |
| EP2150167A4 (en) | SEMI-DISPOSABLE ENDOSKOP | |
| DK2252581T3 (en) | CAPE-SELECTIVE OPIOID RECEPTOR ANTAGONIST | |
| EP2350060A4 (en) | MELANOCORTIN RECEPTOR ANTAGONISTS | |
| BRPI0820447A2 (en) | Glucocorticoid Receptor Agonists | |
| EP1981902A4 (en) | NOGO RECEPTOR ANTAGONISTS | |
| BRPI0907364A2 (en) | N, n-disubstituted aminoalkylbiphenyl prostaglandin d2 receptor antagonists | |
| BRPI0910592A2 (en) | somatostatin receptor 2 antagonists | |
| HRP20170246T1 (en) | DOSAGE MODE FOR SELECTIVE S1P1-RECEPTOR AGONIST | |
| BRPI0912362A2 (en) | nmda receptor antagonist for the treatment of neuropsychiatric disorders | |
| BRPI0810926A2 (en) | CRIG ANTAGONIST | |
| DK2443104T3 (en) | DISUBSTITUTED PHTHALAZINE-HEDGEHOG-STI ANTAGONISTS | |
| EP2490709A4 (en) | GLP-2 RECEPTOR AGONISTS | |
| BRPI0920440A2 (en) | alkylation feed preparation | |
| BRPI0811509A2 (en) | MOUSE | |
| EP2160579A4 (en) | CALORIMETER | |
| BR112012003701A2 (en) | "new quinoline-hepcidin antagonists" | |
| BRPI0918004A2 (en) | glucagon antagonists | |
| DK2364185T3 (en) | DISUBSTITUTED PHTHALAZINE-HEDGEHOG PATHWAY ANTAGONISTS | |
| HUE037394T2 (en) | Clever-1 receptor antagonists to block immune-type 2 macrophages |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 6A E 7A ANUIDADES. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |